Correspondence 0001437749-24-026979 from Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc.
Date: Aug. 15, 2024 · CIK: 0001659617 · Accession: 0001437749-24-026979

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-280951

Date

August 15, 2024

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Moleculin Biotech, Inc.

Letter

Re:

mbrx20240815c_corresp.htm

August 15, 2024

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Moleculin Biotech, Inc.

Registration Statement on Form S-1 (Registration No. 333-280951) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-280951) (the “Registration Statement”), hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Thursday, August 15, 2024, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

	mbrx20240815c_corresp.htm

			August 15, 2024

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

			Re:

			Moleculin Biotech, Inc.

			Registration Statement on Form S-1 (Registration No. 333-280951) -

			Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-280951) (the “Registration Statement”), hereby concurs in the request by Moleculin Biotech, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Thursday, August 15, 2024, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

			Very truly yours,

			H.C. WAINWRIGHT & CO., LLC

			By:         /s/ Edward D. Silvera

			Name: Edward D. Silvera

			Title: Chief Operating Officer

SecProbe.io